IQVIA MIDAS is described on its own product page as "the gold standard in pharmaceutical market measurement", integrating national audits into a globally consistent view across 95 countries, 1.8M products, and 600 diseases.1 The sourcing question underneath, who actually ships the API behind a generic, on what lane, at what concentration, with what compliance trail, is a different surface. PharmaDB is the answer there. As one independent comparison frames it: "IQVIA shows you what was sold. PharmaDB provides trade data and supplier intelligence essential for BD teams."2
Enterprise quote, no published rate card. Datarade's IQVIA listing states plainly: "IQVIA has not published pricing information for their data services. This is common practice for data vendors and providers. Contact IQVIA to obtain current pricing."3 Independent analysis of IQVIA contracts reports that "for larger enterprises with 100 users, costs can easily exceed $50,000 per month", with implementation and data migration adding "$10,000 to over $100,000" on top, plus "hidden costs can arise from data integration, API access, and additional user licenses beyond the initial agreement."4 Comparison reviews describe the contracting model as "custom-quoted, typically requiring a sales process with a dedicated account executive before any data can be accessed."5
Published banded rate card. Lookup fees banded by how many graph queries the agent fires inside a run: $0.20 under 10 lookups, $0.50 for 10 to 50, capped at $1.00 per run for 50+. AI usage at 20% over Anthropic's published rates, line by line in your chat. $100 minimum top-up, credits valid 12 months. Pro tier $5,000 a year covers both lookups and AI, plus watchlist, export, and a forthcoming API. Numbers on the page before the conversation.
IQVIA's strength is demand-side, audited at scale. MIDAS integrates national audits across 95 countries, 1.8M products, and 4M packs.1 National Prescription Audit covers "93% of outpatient prescription activity"; National Sales Perspectives covers "90% of the pharmaceutical market"; Longitudinal Prescription Claims tracks "nearly 4 billion prescription claims per year"; real-world longitudinal datasets cover "over 318M U.S. lives, spanning claims, EMRs, patient-reported outcomes, and real-world wearables data."6,7 The IQVIA Generics product surface centres on patent intelligence, market measurement, and forecasting: ARK Patent Intelligence ("Worldwide Pharmaceutical Patent Information"), MIDAS for sales, and INNsight for "monthly updates on patent protection, new product development and more."8 Across these product pages, trade flows flows by molecule and lane, FDA Type II DMF and EDQM CEP registers, plant inspection trajectories, and median USD per kilogram percentiles are not named as data domains.1,6,8
Trade flows joined to FDA Type II DMF and EDQM CEP registers, plant inspections, warning letters, and import alerts. Lane-level HHI, top-3 exporter share, active-exporter counts, and median USD per kilogram percentiles are first-class objects in the graph.
Commercial, market access, and clinical functions inside large pharma. IQVIA's national audits and MIDAS power "commercial excellence with harmonized global market intelligence", and the Connected Intelligence layer is positioned as the foundation for "actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise."1,9 The day-to-day workflow is brand share, payer mix, launch sequencing, RWE submissions, and market sizing. Independent comparison notes the platform is "built for companies with dedicated data science teams, multi-year vendor relationships, and the organizational capacity to operationalize complex data products."5
API procurement, BD sourcing, supply continuity, finance pre-RFQ. The workflow is "qualify this lane, this quarter, before we issue the order." Designed for the procurement-side counterpart of the commercial team that runs MIDAS: same molecule, opposite end of the value chain.
IQVIA tracks the demand side of sitagliptin: prescription volume, payer mix, generic erosion, and brand-versus-generic share through National Prescription Audit and MIDAS.6,1 Below is the sourcing-side picture for the same molecule, surfaced from PharmaDB's warehouse. Same molecule, orthogonal depth.
The India to US sitagliptin API lane currently has fourteen declared exporters; the top three account for roughly 62% of inbound value, leaving real dual-source room behind them. The IQVIA Januvia page and the PharmaDB page stack rather than substitute. One tells you where the brand-to-generic erosion is happening and how big the market is; the other tells you whether the supply behind the generic launch can carry the order at the price you modelled.
No. They cover different surfaces. IQVIA is the audited demand side: prescription audit, national sales, MIDAS, real-world evidence, market access, commercial analytics. PharmaDB is the sourcing graph underneath: customs, exporter cohorts, plant inspections, dossier registers. Teams that need both run both.
Across the public IQVIA Generics, MIDAS, and Available Data pages, the named data domains are sales, prescriptions, longitudinal claims, EMRs, patient outcomes, patent intelligence, and promotional channel data.1,6,8 Trade flows flows by molecule and lane, exporter shares per lane, lane HHI and top-3 share, plant inspection trajectories, warning letter and import-alert overlays, and median USD per kilogram percentiles on the API side are not named on those pages. PharmaDB ships those as first-class objects.
IQVIA is sold by enterprise quote, with custom contracts and seat counts. Datarade notes plainly that "IQVIA has not published pricing information for their data services."3 Independent analysis reports that "for larger enterprises with 100 users, costs can easily exceed $50,000 per month", with implementation adding "$10,000 to over $100,000".4 PharmaDB is consumption-based: $0.20 per run starting band, $1.00 maximum per run on lookups, plus AI usage at 20% over Anthropic's published rates. $100 minimum top-up. Pro is $5,000 a year covering both lookups and AI, plus watchlist, export, and API.
Probably IQVIA. MIDAS describes itself as "the gold standard in pharmaceutical market measurement", and the audited prescription and sales perspectives are the canonical inputs for share, payer mix, and launch tracking.1,6 PharmaDB adds value when a procurement decision is downstream of the commercial milestone, not when the commercial milestone is the question itself.
Yes, that's the typical pattern we see. Commercial keeps the IQVIA seat for share and forecasting; procurement and BD sourcing add a PharmaDB account for the lane-level supply picture. One independent review describes the alternative being avoided as the all-in-one tax: "a commercial team using IQVIA for Rx claims, a separate vendor for Open Payments, an internal CRM for HCP contacts, and a third system for procedure data is managing four data reconciliation processes."5 Sourcing intelligence is the fifth surface; PharmaDB owns it cleanly and feeds the others by molecule and lane.
There isn't one, because there isn't a switch. PharmaDB sits alongside; the cost is the per-run rate on the questions it newly answers. A common starting pattern is a $100 PAYG top-up on a single live sourcing question (lane HHI, dual-source posture, or a 483 overlay on a candidate supplier) before deciding on Pro. No multi-year commitment, no per-seat fee, no implementation invoice.
Book a 30-minute call. Bring three sourcing questions. We'll run them on the live data with you. No top-up needed, and you keep whatever we find.